David Happel Biography and Net Worth

Chief Executive Officer & Director of Sagimet Biosciences

David Happel joined Sagimet as chief executive officer in October 2022, bringing extensive industry experience, and a strong track record of developing and executing corporate business strategies, raising private and public capital, negotiating M&A transactions, scaling operations and commercializing products. He was most recently president and chief executive officer of Cognoa, a pediatric behavioral health company developing AI-based technologies for developmental and behavioral health conditions, including the first FDA-authorized diagnostic aid, Canvas Dx, for autism. Mr. Happel was previously CEO of Chrono Therapeutics and has held several executive and commercial positions at Horizon Therapeutics, Raptor Pharmaceuticals, Dynavax Technologies and Chiron. Mr. Happel has a BA in chemistry from Indiana University and an MBA from Indiana State University.

What is David Happel's net worth?: The estimated net worth of David Happel is at least $4.38 million as of July 21st, 2025. Mr. Happel owns 689,722 shares of Sagimet Biosciences stock worth more than $4,376,286 as of December 4th. This net worth estimate does not reflect any other assets that Mr. Happel may own. Additionally, Mr. Happel receives an annual salary of $836,180.00 as Chief Executive Officer & Director at Sagimet Biosciences. Learn More about David Happel's net worth.
How old is David Happel?: Mr. Happel is currently 62 years old. There are 3 older executives and no younger executives at Sagimet Biosciences. Learn More on David Happel's age.
What is David Happel's salary?: As the Chief Executive Officer & Director of Sagimet Biosciences Inc., Mr. Happel earns $836,180.00 per year. Learn More on David Happel's salary.
How do I contact David Happel?: The corporate mailing address for Mr. Happel and other Sagimet Biosciences executives is , , . Sagimet Biosciences can also be reached via phone at 650-561-8600 and via email at [email protected]. Learn More on David Happel's contact information.
Has David Happel been buying or selling shares of Sagimet Biosciences?: David Happel has not been actively trading shares of Sagimet Biosciences during the last quarter. Most recently, David Happel sold 65,478 shares of the business's stock in a transaction on Monday, July 21st. The shares were sold at an average price of $9.13, for a transaction totalling $597,814.14. Following the completion of the sale, the chief executive officer now directly owns 689,722 shares of the company's stock, valued at $6,297,161.86. Learn More on David Happel's trading history.
Who are Sagimet Biosciences' active insiders?: Sagimet Biosciences' insider roster includes David Happel (Chief Executive Officer & Director), George Kemble (Chairman), Eduardo Martins (Chief Medical Officer), Elizabeth Rozek (General Counsel), and Beth Seidenberg (Director). Learn More on Sagimet Biosciences' active insiders.
Are insiders buying or selling shares of Sagimet Biosciences?: During the last twelve months, insiders at the sold shares 4 times. They sold a total of 122,223 shares worth more than $1,061,625.27. The most recent insider tranaction occured on November, 20th when Chairman George Kemble sold 37,688 shares worth more than $289,820.72. Insiders at Sagimet Biosciences own 14.7% of the company. Learn More about insider trades at Sagimet Biosciences.
Information on this page was last updated on 11/20/2025.

David Happel Insider Trading History at Sagimet Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/21/2025	Sell	65,478	$9.13	$597,814.14	689,722
3/26/2024	Buy	12,100	$5.27	$63,767.00	639,200
11/16/2023	Buy	590	$2.35	$1,386.50	590

David Happel Buying and Selling Activity at Sagimet Biosciences

Sagimet Biosciences Company Overview

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Today's Range

Now: $6.35

$6.19

$6.55

50 Day Range

MA: $7.56

$6.09

$9.14

2 Week Range

Now: $6.35

$1.73

$11.41

Volume

809,338 shs

Average Volume

478,418 shs

Market Capitalization

$206.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.32

David Happel Biography and Net Worth

What is David Happel's net worth?

How old is David Happel?

What is David Happel's salary?

How do I contact David Happel?

Has David Happel been buying or selling shares of Sagimet Biosciences?

Who are Sagimet Biosciences' active insiders?

Are insiders buying or selling shares of Sagimet Biosciences?